DIGITAL-VAULT-SERVICES
15.4.2024 09:01:30 CEST | Business Wire | Press release
Digital Vault Services:
- Siemens chooses Digital Vault Services (DVS) for guarantee digitization.
- Collaboration with Digital Vault Services reflects Siemens commitment to innovation and efficiency.
- DVS’s Guarantee Vault Platform enables Siemens to optimize workflow efficiency and enhance security in guarantee management.
Siemens, a technology company focused on industry, infrastructure, transport, and healthcare, chooses Digital Vault Services for guarantee digitization, reflecting its dedication to innovation and efficiency. Through the integration of Digital Vault Services' innovative Guarantee Vault Platform (GVP), Siemens propels its digital transformation journey within its Guarantee Business, leveraging technology to optimize operations and enhance customer satisfaction.
The adoption of the Guarantee Vault will empower Siemens for streamlined and digitized guarantee processes. With GVP integrated into its operations, Siemens will benefit from GVP’s unchallenged capabilities to seamlessly connect to the entire guarantee ecosystem including all bank and insurance partners.
Gerhard Heubeck, Global Head Trade Finance Advisory at Siemens, commented, “We are pleased to announce our partnership with Digital Vault Services. As an active member of the working group, we have always been convinced of GVP's capabilities to significantly improve our collaboration and communication with our financial partners and to eliminate time-consuming, manual and paper-based processes. By leveraging GVP's innovative features, we can now engage in efficient, fast, and paperless interactions, while fully digitizing the end-to-end process from our organization through our financial partners to our valued customers. “
"We are thrilled to collaborate with Siemens, a key member of the working group that contributed to the development of our Guarantee Vault Platform," said Ludger Janßen, Co-CEO of Digital Vault Services. "Siemens commitment to innovation aligns perfectly with our mission to digitize the entire guarantee ecosystem and helps with the digital transformation of the financial industry. Together, we will drive significant advancements in guarantee processing efficiency and security."
Jaime Gimeno, Co-CEO of Digital Vault Services added: "With digital guarantees issued, secured and safekept on Guarantee Vault, Siemens and its customers are well positioned to achieve maximum efficiency and transparency. We do all this using best in class technology secured to ISO 27001 standards to keep our customers safe. We welcome Siemens to our network and look forward to working with them on their digitization journey."
About Digital Vault Services
Digital Vault Services GmbH revolutionizes the guarantee journey with its Guarantee Vault, boosting complete digitization. This solution offers a seamless, paperless experience, transforming the guarantee ecosystem end to end. Applicants can request all types of guarantees globally within one central tool, while banks and insurers securely issue and store guarantees. Beneficiaries enjoy seamless interaction and can manage and access the guarantees anytime. Innovative features such as beneficiary read confirmation and pre-approved wording libraries enhance processing speed, transparency, and efficiency. With top-tier security standards and API integration for seamless connectivity, DVS ensures a robust solution for all guarantee- business needs.
Founded in 2018 through collaboration with 16 industry participants, banks and insurers, Digital Vault Services has rapidly evolved. Since its launch in 2021, Guarantee Vault has gained strong traction in Germany and is now expanding into other European markets, including the Nordic countries, where future presence has already been announced. The company’s headquarters are located in Munich, Germany.
About Siemens
Siemens AG (Berlin and Munich) is a leading technology company focused on industry, infrastructure, transport, and healthcare. From more resource-efficient factories, resilient supply chains, and smarter buildings and grids, to cleaner and more comfortable transportation as well as advanced healthcare, the company creates technology with purpose adding real value for customers. By combining the real and the digital worlds, Siemens empowers its customers to transform their industries and markets, helping them to transform the everyday for billions of people. Siemens also owns a majority stake in the publicly listed company Siemens Healthineers, a globally leading medical technology provider shaping the future of healthcare. In fiscal 2023, which ended on September 30, 2023, the Siemens Group generated revenue of €77.8 billion and net income of €8.5 billion. As of September 30, 2023, the company employed around 320,000 people worldwide. Further information is available on the Internet at www.siemens.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240412273459/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom